Primary Ciliary Dyskinesia (PCD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Primary Ciliary Dyskinesia (PCD) Market Outlook
Thelansis’s “Primary Ciliary
Dyskinesia (PCD) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2024 To 2034" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Primary
Ciliary Dyskinesia (PCD) treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
Primary
Ciliary Dyskinesia (PCD) Overview
Primary
ciliary dyskinesia (PCD) is predominantly inherited as an autosomal recessive
disorder, leading to recurrent and chronic upper and lower respiratory tract
infections. In 40–50% of cases, PCD is associated with mirror-image organ
arrangement and other forms of heterotaxy. Currently, pathogenic variants in 45
genes have been identified as causes of PCD. While PCD is typically inherited
in an autosomal recessive manner, exceptions include FOXJ1-PCD (autosomal
dominant), PIH1D3-PCD, and OFD1-PCD (X-linked). Notably, 20%-30% of individuals
with well-characterized PCD lack identifiable pathogenic variants in any
associated genes. The progression and severity of lung disease in PCD vary
among individuals. More than 75% of full-term neonates with PCD experience
“neonatal respiratory distress,” necessitating supplemental oxygen for days to
weeks despite term gestation. However, few are diagnosed with PCD at this age.
Chronic airway infection becomes evident in early childhood, with most children
presenting chronic year-round wet cough, sputum production, and chronic
wheezing
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment